It is frequently expressed in pancreatic cancer and retinoblastoma cells, implicating an oncogenic function, while PAX6 is recognized as a tumor suppressor in gliomas and prostate cancer [6], [10], [11], [20], [21].PAX6 expression is significantly reduced in glioblastomas and the expression level is correlated with longer patient survival [22]. Here, PAX6 is linked to pancreatic neoplasm.